Page 6,533«..1020..6,5326,5336,5346,535..6,5406,550..»

Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study

Posted: Published on September 8th, 2012

THURSDAY, Sept. 6 (HealthDay News) -- A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested. Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating autoimmune disorder that causes inflammation of the lining of the joints. Biologics work by targeting specific parts of the immune system involved in the inflammation process. Previous studies have raised questions about whether the drugs might boost the risk of cancer. The new study appears in the Sept. 5 issue of the Journal of the American Medical Association. The researchers, led by a researcher at the University of Texas M.D. Anderson Cancer Center, looked at 63 randomized controlled trials of the drugs that featured follow-up periods of at least 24 weeks. In total, the studies analyzed nearly 29,500 patients. The biologic medications are abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), and tocilizumab (Actemra). The analysis didn't find any extra risk of cancer compared to other drugs for rheumatic arthritis or a placebo. … Continue reading

Posted in Drugs | Comments Off on Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study

USF Health Selects Tampa's Bisk Education to Expand Online Degree Offerings

Posted: Published on September 8th, 2012

TAMPA, Fla., Sept. 7, 2012 /PRNewswire/ --USF Health has selected Bisk Education's University Alliance division to assist in developing and delivering online degree programs. Representatives from each organization, both long-time institutions in Tampa, met at Bisk's Sabal Park headquarters on Friday, August 17 to finalize the agreement. USF President Judy Genshaft, Ph.D., met with Nathan Bisk, Founder, Chairman, and CEO of Bisk Education, Inc., and Andy Titen, President and Chief Operating Officer, to sign the contract that will expand the online delivery of USF's highly acclaimed academic programs. "I believe that providing students with increased opportunities for online learning is imperative to their success," said Dr. Genshaft. "Partnering with Bisk Education is a vital part of accomplishing this goal." In addition to Dr. Genshaft, representatives in attendance included Dr. Stephen Klasko, Chief Executive Officer of USF Health and Dean of the Morsani College of Medicine; Michael Barber, D.Phil., Associate Dean for Graduate and Postdoctoral Affairs; John Ekarius, Chief Operating Officer of USF Health and the Morsani College of Medicine; John W. Long, Chief Operating Officer of USF; Hilary Black, JD, Associate General Counsel of USF; Lisa Greene, Director of Strategic Communications for USF Health; and Dana Tirrell, Project Manager. The … Continue reading

Posted in Online Pharmacy | Comments Off on USF Health Selects Tampa's Bisk Education to Expand Online Degree Offerings

Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress

Posted: Published on September 7th, 2012

MADISON, Wis., Sept. 7, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that three clinical imaging posters based on research conducted by Lance Hall, M.D., Anne M. Traynor, M.D., Glenn Liu, M.D., Jamey Weichert, Ph.D. and their colleagues are being presented at the World Molecular Imaging Congress taking place September 5-8, 2012 in Dublin, Ireland. These presentations describe initial findings in advanced cancer patients that demonstrate selective and prolonged uptake of Novelos' PET imaging and therapeutic compounds in a range of tumor types. Dr. Hall is Assistant Professor of Radiology, Dr. Traynor is Associate Professor of Medicine, Dr. Liu is Associate Professor of Medicine and Dr. Weichert is Associate Professor of Radiology, all in the School of Medicine and Public Health at the University of Wisconsin, Madison and all are members of the UW Carbone Cancer Center. Dr. Weichert is also the Chief Scientific Officer of Novelos and the founder of Novelos' technology. "We are consistently seeing cancer-selective tumor uptake and prolonged retention across multiple tumor types with I-124-CLR1404 (LIGHT) and I-131-CLR1404 (HOT)," said Dr. Hall. "LIGHT has potential as a stand-alone PET imaging agent for … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress

Stem cell treatment gives Honolulu dog better life

Posted: Published on September 7th, 2012

Dog receives stem cell therapy In recent years, Kumba, a 13-year-old rottweiler mix, and beloved pet, had been living a life in pain. "Kumba had a lot of problems with his back legs; both his hips and his knees were affected by really severe arthritis and he was having a hard time getting up and down and his quality of life was really being affected," said Dr. Cristina Miliaresis, who is a veterinarian at Surf Paws Veterinary Hospital in Hawaii Kai. Reports show it's a painful problem affecting up to 40 percent of the 164 million cats and dogs in the United States. "When we heard about the therapy, it was an option for us and for Kumba to live a better quality of life," said Kumbas owner Rumi Hospedar. In June, veterinarians took fat tissue from Kumba's shoulder, separated the stem cells, then injected it back into his ailing joints. In the past, veterinarians had to send tissue to the mainland, but a company called MediVet provided the equipment to do it all in clinic. "He came back today so we could check up on him and see how he's doing," said Dr. Miliaresis. She said most of their … Continue reading

Comments Off on Stem cell treatment gives Honolulu dog better life

Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells

Posted: Published on September 7th, 2012

Public release date: 6-Sep-2012 [ | E-mail | Share ] Contact: Sally Stewart Sally.stewart@cshs.org 310-248-6566 Cedars-Sinai Medical Center LOS ANGELES Sept. 6, 2012 A team of Cedars-Sinai Heart Institute stem cell researchers today was awarded a $1.3 million grant from the California Institute of Regenerative Medicine to continue study of an experimental stem cell therapy that treats heart attack patients with heart-derived cells. Earlier this year, data from the first clinical trial of the stem cell treatment showed the therapy helped damaged hearts regrow healthy muscle. To date, this cell therapy, developed by Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and Mark S. Siegel Family Professor, is the only treatment shown to regenerate the injured human heart. In this therapy, human heart tissue is used to grow specialized heart stem cells, which then are injected back into the patient's heart. The new research will focus on understanding the cellular mechanisms that have produced favorable outcomes. "We have seen encouraging results in patients with this treatment, and it has the potential to revolutionize how we treat heart attack patients," Marbn said. "This further study will allow us to better understand how it works, which we hope will lead … Continue reading

Comments Off on Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells

Sarepta's Selling — Should You Be Buying?

Posted: Published on September 7th, 2012

Sarepta Therapeutics (Nasdaq: SRPT) announced an at-the-market equity offering sales agreement with Citadel Securities on Tuesday. Under the terms of the agreement, the company can offer and sell up to $40 million of its common stock. With Sarepta selling (or at least clearing the way to sell), is now a good time for investors to buy? Let's take a look. Buy? The single most compelling reason to buy Sarepta is the promise of its eteplirsen drug in treating Duchenne muscular dystrophy, or DMD. There are currently no disease-modifying therapies available for the condition. Eteplirsen shows great potential for treating DMD. Sarepta announced positive results in April from its phase 2b clinical trial. The study found that the drug produced consistent levels of dystrophin, the protein needed for muscular function that is lacking in patients with DMD. In July, the company announced even better news. Treatment with eteplirsen over a 36-week period achieved significant clinical benefits for patients. Dr. Jerry Mendell, director of the centers for gene therapy and muscular dystrophy at Nationwide Children's Hospital and principle investigator of the phase 2b study, stated that eteplirsen was "the most promising advance to treat the underlying cause of muscular dystrophy I've seen … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta's Selling — Should You Be Buying?

Nutritional supplement offers promise in treatment of unique form of autism

Posted: Published on September 7th, 2012

ScienceDaily (Sep. 6, 2012) An international team of researchers, led by scientists at the University of California, San Diego and Yale University schools of medicine, have identified a form of autism with epilepsy that may potentially be treatable with a common nutritional supplement. The findings are published in the Sept. 6, 2012 online issue of Science. Roughly one-quarter of patients with autism also suffer from epilepsy, a brain disorder characterized by repeated seizures or convulsions over time. The causes of the epilepsy are multiple and largely unknown. Using a technique called exome sequencing, the UC San Diego and Yale scientists found that a gene mutation present in some patients with autism speeds up metabolism of certain amino acids. These patients also suffer from epileptic seizures. The discovery may help physicians diagnose this particular form of autism earlier and treat sooner. The researchers focused on a specific type of amino acid known as branched chain amino acids or BCAAs. BCAAs are not produced naturally in the human body and must be acquired through diet. During periods of starvation, humans have evolved a means to turn off the metabolism of these amino acids. It is this ability to shut down that metabolic … Continue reading

Comments Off on Nutritional supplement offers promise in treatment of unique form of autism

Rare form of autism could be treated with common nutritional supplement

Posted: Published on September 7th, 2012

Researchers may have discovered a potential treatment for a rare form of autism marked by epileptic seizures a simple nutritional supplement. In a recent international study, a team of scientists from the University of California, San Diego and Yale University schools of medicine have identified a genetic mutation in certain patients suffering from this unique type of autism. After performing what is known as exome sequencing a type of selective genome sequencing the team found that these patients speed up the metabolism of specific amino acids called branched chain amino acids, or BCAAs. According to Autism Speaks, approximately one-third of those suffering from autism also suffer from epilepsy, a neurological disorder marked by periods of seizure or convulsion. The discovery could lead to better understanding of the mechanisms behind autism and epilepsy, as well as lead to ways to treat the condition sooner. After recognizing this deficiency in BCAAs, the researchers thought that a large supplement of amino acids would help to compensate for their faster metabolisms. These are amino acids we cant produce in our bodies, Gaia Novarino, a staff scientist in the UCSD Department of Neurosciences and the studys first author, told FoxNews.com. So we have to take … Continue reading

Comments Off on Rare form of autism could be treated with common nutritional supplement

‘Need to change mindset of rural folk on stroke’

Posted: Published on September 7th, 2012

by Saiful Bahari, reporters@theborneopost.com. Posted on September 7, 2012, Friday CONGRATULATIONS: Fatimah (centre) presenting a certificate of achievement to one of the patients who attended the session at the centre as Azerina (second left), Empiang (left) and an unidentified person look on. Photo by Chimon Upon KUCHING: There is a need to educate the rural community on stroke and its threats, symptoms and the importance of getting proper treatment and rehabilitation. Women, Welfare and Family Development Minister Datuk Fatimah Abdullah, who pointed this out, said there were many cases of people in the rural areas, especially senior citizens, refusing to go for treatment or rehabilitation due to the belief that doing so would make matters worse. Some of those in the rural were not well informed of the medical conditions or complications, and they had the perception that by going for treatment in hospitals, the condition will worsen, said Fatimah, who pointed out that some still hung to the belief that there was no necessity to seek medical treatment in hospitals. This mentality, according to her, needed to be changed as some cases, especially those in the early stages, could be cured. She was speaking at the Hari Raya Ramah … Continue reading

Comments Off on ‘Need to change mindset of rural folk on stroke’

Mom's charity helps spinal cord injury victims

Posted: Published on September 7th, 2012

It was supposed to be one of the best weekends of his life. While in Florida to attend the 2010 Superbowl, Anthony Purcell was enjoying a morning at a Miami beach in waters he had grown up in as a child before moving to California. At 22, the part-time model and student and former high school sports star had his whole life ahead of him. Micki Purcell and son Anthony, before his spinal cord injury accident deemed him paralyzed. PHOTO COURTESY WALKING WITH ANTHONY ADVERTISEMENT But in a life-changing second, Anthony accidentally dove into a sandbar, breaking his neck and bruising his C5 and C6 vertebrae. Luckily, his cousin Bernie pulled him ashore and quickly got him the necessary medical attention that would save his life. But after a four-hour surgery and only three weeks in the hospital, Anthony was released with the dismal prognosis given to so many with spinal cord injury (SCI): Anthony was told he'd never walk again. When it comes to SCIs, most insurance companies find the rehabilitation prospects too grim and costly. But Anthonys mother, Micki Purcell, was not one to simply accept the bad news, and luckily, she had the finances to explore other … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Mom's charity helps spinal cord injury victims

Page 6,533«..1020..6,5326,5336,5346,535..6,5406,550..»